Log in

Integra Lifesciences Stock Price, News & Analysis (NASDAQ:IART)

$60.23
-1.55 (-2.51 %)
(As of 10/23/2019 08:53 AM ET)
Today's Range
$60.23
Now: $60.23
$61.93
50-Day Range
$57.87
MA: $60.59
$63.75
52-Week Range
$42.14
Now: $60.23
$65.09
Volume250,986 shs
Average Volume298,832 shs
Market Capitalization$5.15 billion
P/E Ratio24.89
Dividend YieldN/A
Beta1.1
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:IART
CUSIP45798520
Phone609-275-0500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.47 billion
Cash Flow$3.67 per share
Book Value$16.15 per share

Profitability

Net Income$60.80 million

Miscellaneous

Employees4,500
Market Cap$5.15 billion
Next Earnings Date10/24/2019 (Confirmed)
OptionableOptionable

Receive IART News and Ratings via Email

Sign-up to receive the latest news and ratings for IART and its competitors with MarketBeat's FREE daily newsletter.


Integra Lifesciences (NASDAQ:IART) Frequently Asked Questions

What is Integra Lifesciences' stock symbol?

Integra Lifesciences trades on the NASDAQ under the ticker symbol "IART."

When did Integra Lifesciences' stock split? How did Integra Lifesciences' stock split work?

Integra Lifesciences shares split on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly minted shares were issued to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of Integra Lifesciences stock prior to the split would have 200 shares after the split.

How were Integra Lifesciences' earnings last quarter?

Integra Lifesciences Holdings Corp (NASDAQ:IART) announced its quarterly earnings results on Wednesday, October, 31st. The life sciences company reported $0.59 EPS for the quarter, hitting analysts' consensus estimates of $0.59. The life sciences company earned $365.85 million during the quarter, compared to the consensus estimate of $367.89 million. Integra Lifesciences had a return on equity of 16.30% and a net margin of 6.76%. Integra Lifesciences's revenue was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.45 earnings per share. View Integra Lifesciences' Earnings History.

When is Integra Lifesciences' next earnings date?

Integra Lifesciences is scheduled to release their next quarterly earnings announcement on Thursday, October 24th 2019. View Earnings Estimates for Integra Lifesciences.

How can I listen to Integra Lifesciences' earnings call?

Integra Lifesciences will be holding an earnings conference call on Thursday, October 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for IART?

11 brokers have issued twelve-month target prices for Integra Lifesciences' stock. Their forecasts range from $50.00 to $75.00. On average, they anticipate Integra Lifesciences' share price to reach $62.18 in the next year. This suggests a possible upside of 3.2% from the stock's current price. View Analyst Price Targets for Integra Lifesciences.

What is the consensus analysts' recommendation for Integra Lifesciences?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Integra Lifesciences in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Integra Lifesciences.

What are Wall Street analysts saying about Integra Lifesciences stock?

Here are some recent quotes from research analysts about Integra Lifesciences stock:
  • 1. According to Zacks Investment Research, "Integra LifeSciences exited the second quarter of 2019 on a strong note with better-than-expected results. Organic revenue growth was encouraging and was above the company’s expectation. Within global neurosurgery business, sales in dural access and repair increased in low-single digits on an organic basis with growth in both graft and sealant product lines. Benefiting from product launches and an enhanced sales force performance, the company envisions faster organic growth during the second half of 2019. On the flip side, escalating costs and expenses have been a major headwind for Integra Lifesciences. A tough competitive landscape adds to the woes.  Overall, Integra LifeSciences outperformed its industry in the past three months." (9/2/2019)
  • 2. Cantor Fitzgerald analysts commented, "We maintain our Neutral rating and 12-month price target of $50 on IART. Although we view IART’s long-range plan as impressive, we believe execution over the next few quarters is critical to restoring investor confidence in the stock. We think it is appropriate to stay on the sidelines at this time, but we might become more positive on the stock if the company were to execute on its integration and salesforce restructuring goals. We think IART is fairly valued at current levels, appropriately balancing the long-term opportunities with the risk of near-term disruption from the Codman acquisition and the changes to the OTT sales channel structure." (2/21/2019)

Has Integra Lifesciences been receiving favorable news coverage?

News stories about IART stock have trended negative recently, according to InfoTrie. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Integra Lifesciences earned a media sentiment score of -2.5 on InfoTrie's scale. They also assigned news headlines about the life sciences company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Integra Lifesciences.

Are investors shorting Integra Lifesciences?

Integra Lifesciences saw a decrease in short interest in the month of September. As of September 30th, there was short interest totalling 1,040,000 shares, a decrease of 5.5% from the August 30th total of 1,100,000 shares. Based on an average daily volume of 412,200 shares, the short-interest ratio is presently 2.5 days. Approximately 1.5% of the shares of the stock are sold short. View Integra Lifesciences' Current Options Chain.

Who are some of Integra Lifesciences' key competitors?

What other stocks do shareholders of Integra Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra Lifesciences investors own include Intel (INTC), Celgene (CELG), Gilead Sciences (GILD), GW Pharmaceuticals PLC- (GWPH), NVIDIA (NVDA), Square (SQ), Adobe (ADBE), Align Technology (ALGN), Alexion Pharmaceuticals (ALXN) and Activision Blizzard (ATVI).

Who are Integra Lifesciences' key executives?

Integra Lifesciences' management team includes the folowing people:
  • Mr. Peter J. Arduini, Pres, CEO & Director (Age 54)
  • Dr. Richard E. Caruso Ph.D., Founder and Chairman Emeritus (Age 76)
  • Mr. Glenn G. Coleman, Corp. VP of International & CFO (Age 51)
  • Mr. Daniel L. Reuvers, Corp. VP and Pres of Specialty Surgical Solutions (Age 56)
  • Mr. Robert T. Davis Jr., Corp. VP and Pres of Orthopedics & Tissue Technologies (Age 60)

Who are Integra Lifesciences' major shareholders?

Integra Lifesciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Tributary Capital Management LLC (0.57%), CWM LLC (0.18%), Envestnet Asset Management Inc. (0.06%), Nisa Investment Advisors LLC (0.04%), Pacer Advisors Inc. (0.03%) and State of Michigan Retirement System (0.02%). Company insiders that own Integra Lifesciences stock include Barbara B Hill, Christian S Schade, Daniel L Reuvers, Glenn Coleman, Jeffrey Mosebrook, John Mooradian, Joseph Vinhais, Keith Bradley, Kenneth Burhop, Lisa Evoli, Peter J Arduini, Raymond G Murphy, Rhonda Germany Ballintyn, Richard D Gorelick, Richard E Caruso and Stuart Essig. View Institutional Ownership Trends for Integra Lifesciences.

Which major investors are selling Integra Lifesciences stock?

IART stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, Pacer Advisors Inc., Diversified Trust Co, Crossmark Global Holdings Inc. and State of Michigan Retirement System. Company insiders that have sold Integra Lifesciences company stock in the last year include Christian S Schade, Daniel L Reuvers, Glenn Coleman, John Mooradian, Kenneth Burhop, Lisa Evoli, Peter J Arduini, Raymond G Murphy and Richard E Caruso. View Insider Buying and Selling for Integra Lifesciences.

Which major investors are buying Integra Lifesciences stock?

IART stock was bought by a variety of institutional investors in the last quarter, including CWM LLC, Nisa Investment Advisors LLC, Strs Ohio, Cerebellum GP LLC, State of Alaska Department of Revenue, World Asset Management Inc, Envestnet Asset Management Inc. and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought Integra Lifesciences stock in the last two years include Barbara B Hill and Rhonda Germany Ballintyn. View Insider Buying and Selling for Integra Lifesciences.

How do I buy shares of Integra Lifesciences?

Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Integra Lifesciences' stock price today?

One share of IART stock can currently be purchased for approximately $60.23.

How big of a company is Integra Lifesciences?

Integra Lifesciences has a market capitalization of $5.15 billion and generates $1.47 billion in revenue each year. The life sciences company earns $60.80 million in net income (profit) each year or $2.42 on an earnings per share basis. Integra Lifesciences employs 4,500 workers across the globe.View Additional Information About Integra Lifesciences.

What is Integra Lifesciences' official website?

The official website for Integra Lifesciences is http://www.integralife.com/.

How can I contact Integra Lifesciences?

Integra Lifesciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at 609-275-0500 or via email at [email protected]


MarketBeat Community Rating for Integra Lifesciences (NASDAQ IART)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  384 (Vote Outperform)
Underperform Votes:  448 (Vote Underperform)
Total Votes:  832
MarketBeat's community ratings are surveys of what our community members think about Integra Lifesciences and other stocks. Vote "Outperform" if you believe IART will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IART will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel